HARVONI Drug Patent Profile

Which patents cover Harvoni, and what generic alternatives are available?

Harvoni is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are seventeen patents protecting this drug.

This drug has five hundred and sixty-five patent family members in fifty countries.

The generic ingredient in HARVONI is ledipasvir; sofosbuvir. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ledipasvir; sofosbuvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Harvoni

Harvoni was eligible for patent challenges on October 10, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 14, 2032. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for HARVONI

International Patents:	565
US Patents:	17
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HARVONI

US Patents and Regulatory Information for HARVONI

HARVONI is protected by seventeen US patents and four FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-001	Oct 10, 2014		RX	Yes	Yes					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	TABLET;ORAL	205834-002	Aug 28, 2019		RX	Yes	No					Y
Gilead Sciences Inc	HARVONI	ledipasvir; sofosbuvir	PELLETS;ORAL	212477-002	Aug 28, 2019		RX	Yes	Yes					Y

International Patents for HARVONI

When does loss-of-exclusivity occur for HARVONI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Germany

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

New Zealand

Paraguay

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HARVONI around the world.

Country	Patent Number	Title	Estimated Expiration
Peru	20141296
Mexico	2014006373
European Patent Office	3321275

Supplementary Protection Certificates for HARVONI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2430014	PA2016002,C2430014	Lithuania		PRODUCT NAME: LEDIPASVIRAS; REGISTRATION NO/DATE: EU/1/14/958(001-002) 20141117
2430014	300796	Netherlands		PRODUCT NAME: LEDIPASVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/14/958 20141118
2430014	201640001	Slovenia		PRODUCT NAME: LEDIPASVIR; NATIONAL AUTHORISATION NUMBER: EU/1/14/958/001-002; DATE OF NATIONAL AUTHORISATION: 20141117; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Investment Scenario, Market Dynamics, and Financial Trajectory of HARVONI (Ledipasvir and Sofosbuvir)

Last updated: February 3, 2026

Summary

HARVONI (ledipasvir and sofosbuvir) is a breakthrough hepatitis C virus (HCV) treatment developed by Gilead Sciences. Approved by the FDA in 2014, HARVONI has significantly transformed HCV management through its high cure rates and simplified dosing. Key factors influencing its market trajectory include evolving treatment guidelines, patent protections, competitive landscape, and pricing strategies. This report offers a comprehensive analysis of the current market environment, future growth prospects, competitive threats, and investment considerations related to HARVONI.

---

What Is the Current Investment Scenario for HARVONI?

Market Position and Revenue Generation

Year	Global Sales (USD Millions)	Market Share	Notes
2015	1,321	90%	Dominated initial HCV cure market
2016	2,222	87%	Sustained dominance
2017	2,639	80%	Increased competition emergence
2018	2,260	75%	Patent expiration rumors surface
2019	1,800	65%	Entry of generic competitors, price pressure
2020	1,500	60%	Continued generic market penetration
2021	1,300	55%	Market saturation, regional growth opportunities

Source: EvaluatePharma, 2022

Revenue Trends

• Primary revenue driven by US and European Markets
• Emerging markets (Asia, Latin America) show promise due to expanding healthcare coverage
• Patent expiration scheduled for 2025-2026 (subject to legal challenges or extensions)

Investment Rationale

• Stable cash flows driven by existing patents
• Potential growth in non-US markets owing to increasing HCV screening programs
• Pipeline developments: Gilead's pipeline includes next-generation HCV agents and combination therapies, potentially extending revenue streams

---

How Do Market Dynamics Influence HARVONI’s Future Value?

Market Drivers

Driver	Impact	Source/Notes
Rising HCV Diagnosis Rates	Expands potential patient pool	CDC reports, WHO HCV Global Report 2022
Treatment Guidelines Evolution	Favorable guidelines increase access	AASLD/IDSA 2022 update
Pricing and Reimbursement Policies	Affects affordability and adoption	Varies by country, price controls
Generic Competition	Reduces margins, pressures pricing	Patent cliff from 2025
Advances in HCV Diagnostics	Facilitate early detection, boosting market size	New PCR-based rapid tests
COVID-19 Impact	Disrupts healthcare systems but prompts telemedicine	Ongoing, April 2023 data

Competitive Landscape

Competitor	Product Name	Market Share (%)	Notes
Gilead Sciences	HARVONI, Epclusa	55-60	Market leader, patent protections in place
AbbVie	Mavyret	20-25	Lower price, broad genotype activity
BMS, Merck, Others	Various generics/novels	15-20	Loss of exclusivity, emerging alternatives

Policy and Regulatory Environment

• Patent protections are critical for maintaining market exclusivity until 2025-26.
• Generic approval pathways in key markets threaten revenue post-patent expiry.
• Pricing negotiations in countries like the UK (NHS) and Canada impact margins.

---

What Is the Financial Trajectory for HARVONI?

Revenue Projections (2023-2030)

Year	Estimated Revenue (USD Millions)	Assumptions
2023	1,200	Minor market share decline, ongoing sales
2024	1,000	Increased generic competition, price erosion
2025	700	Patent expiry, entry of generics
2026	500	Generic market captured, price reductions
2027-2030	Stabilization or decline	Transition to new therapies or market exit

Note: These figures incorporate the impact of patent expiration, market saturation, and regional growth initiatives.

Profit Margins and Cost Structure

Parameter	Value / Range	Notes
Gross Margin	~85%	High due to pricing power and low manufacturing costs
R&D Expense	USD 500M+ annually	Focused on pipeline and next-generation agents
Operating Expenses	USD 1B+ annually	Marketing, distribution, legal, and administrative

Valuation Methodologies

• Discounted Cash Flow (DCF): Future revenues discounted at a weighted average cost of capital (WACC) of approximately 8-10%.
• Comparable Company Analysis: Comparing Gilead's HCV franchise to peers like AbbVie, Merck, and BMS.

Investment Risks

Risk Factor	Impact	Mitigation Strategies
Patent Expiry & Generics	Revenue erosion post-2025	Accelerate pipeline, expand into new markets
Regulatory Challenges	Delays or restrictions on new approvals	Robust compliance and stakeholder engagement
Pricing Pressures	Lower margins in developed markets	Differential pricing strategies
Market Competition	Loss of market share due to newer therapies	Innovation pipeline, strategic collaborations

---

How Does HARVONI Compare With Competitors and Alternatives?

Criteria	HARVONI	Mavyret	Epclusa	New Therapies (e.g., voxilaprevir)
Indicated Genotypes	1, 4, 5, 6	1-6	1-6	1, 2, 3, 4, 5, 6
Treatment Duration	8-12 weeks	8 weeks	12 weeks	Variable
Cure Rate	>95%	>95%	>95%	Similar or higher
Side Effect Profile	Favorable	Favorable	Favorable	Similar or improved
Price (USD per treatment)	Approx. USD 60,000	Approx. USD 26,000	Approx. USD 24,000	Varies

Note: Price comparisons are approximate, based on list prices and generally negotiated discounts.

---

Key Investment Considerations

• Patent expiration around 2025-2026 poses significant revenue risks.
• Market saturation in developed countries limits growth but regional expansion offers opportunities.
• Pipeline innovation remains critical for sustaining revenue; Gilead's pipeline includes next-generation HCV treatments and potential cures for other viral infections.
• Pricing and reimbursement dynamics in emerging markets are evolving, presenting both risks and growth avenues.
• Competitive pressures from generic manufacturers demand strategic patent management and portfolio diversification.

---

Deep-Dive Analysis: Comparative Revenue Forecasts Table

Year	HARVONI (USD Mill)	Mavyret (USD Mill)	Epclusa (USD Mill)	Total Market Loss (USD Mill)	Key Notes
2023	1,200	600	500	300	Patent protection persists; generic competition begins to rise
2024	1,000	720	580	520	Entry of generics accelerates; price reductions dominate
2025	700	700	480	1,200	Patent expiry, generics gain significant market share
2026	500	800	520	2,000	Market shifts heavily toward generics
2027-2030	Stabilizing decline	Declining as patents remain	Continued erosion	Total market contracts	Enterprise shifts focus towards pipeline and new indications

---

FAQs

Q1: When does HARVONI's patent protection officially expire?
A: US patents for HARVONI are expected to expire around 2025-2026, subject to legal challenges, patent extensions, and regulatory decisions.

Q2: How does the entry of generics impact HARVONI's market share and revenue?
A: Generics significantly reduce prices and market share, especially post-patent expiry, risking up to 50-70% revenue decline if the market fully transitions.

Q3: What opportunities exist for Gilead with HARVONI?
A: Expanding into emerging markets, integrating with new diagnostic technologies, and developing next-generation therapies are key opportunities.

Q4: How does HARVONI compare to newer HCV treatments in development?
A: While newer agents may offer shorter treatment durations or broader genotype coverage, HARVONI maintains a strong position due to its proven efficacy and established market presence.

Q5: What regulatory or policy changes could influence HARVONI’s market?
A: Price control measures, reimbursement policies, and accelerated approval pathways could either constrain or facilitate market access and profitability.

---

Key Takeaways

• Market sustainability is under threat from patent expiry and rising generic competition; strategic planning must focus on pipeline development and market diversification.
• Emerging markets present growth opportunities, driven by increasing HCV awareness, screening, and healthcare reforms.
• Pricing strategies and negotiations will critically influence revenue, especially in countries with tight healthcare budgets.
• Innovation pipeline is vital; Gilead’s focus on next-generation HCV therapies and antiviral agents could extend product life cycles.
• Investment risk management should account for potential revenue erosion post-2025, with proactive portfolio management and expansion into new indications.

---

Sources:

1. EvaluatePharma, 2022
2. Gilead Sciences Annual Reports, 2014-2022
3. CDC Hepatitis Surveillance, 2022
4. AASLD/IDSA Clinical Practice Guidelines, 2022
5. World Health Organization Hepatitis C Fact Sheet, 2022